

## Original article

## Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis

Wouter P. Nieuwenhuis<sup>1</sup>, Hanna W. van Steenberghe<sup>1</sup>, Lukas Mangnus<sup>1</sup>, Elize C. Newsum<sup>1</sup>, Johan L. Bloem<sup>2</sup>, Tom W. J. Huizinga<sup>1</sup>, Saskia le Cessie<sup>3,4</sup>, Monique Reijnders<sup>2</sup> and Annette H. M. van der Helm-van Mil<sup>1</sup>

## Abstract

**Objectives.** To assess the diagnostic value of MRI for early RA. In some RA patients, a classifiable diagnosis cannot be made at first presentation; these patients present with unclassified arthritis (UA). The use of MRI for early diagnosis of RA is recommended, yet the evidence for its reliability is limited.

**Methods.** MRI of hand and foot was performed in 589 early arthritis patients included in the Leiden Early Arthritis Clinic (229 presented with RA, 159 with other arthritides and 201 with UA). Symptom-free controls provided a reference for defining an abnormal MRI. In preliminary investigations, MRI of patients who presented with RA was compared with MRI of symptom-free controls and of patients with other arthritides. Thereafter, the value of MRI in early RA diagnosis was determined in UA patients using the 1-year follow-up on fulfilling the 1987 RA criteria and start of disease-modifying drugs as outcomes.

**Results.** Preliminary investigations were promising. Of the UA patients, 14% developed RA and 37% started disease-modifying treatment. MRI-detected tenosynovitis was associated with RA development independent of other types of MRI-detected inflammation [odds ratio (OR) = 7.5, 95% CI: 2.4, 23] and also independent of age and other inflammatory measures (swollen joints, CRP) (OR = 4.2, 95% CI: 1.4, 12.9). Within UA patients, the negative predictive value of abnormal tenosynovitis was 95% (95% CI: 89%, 98%) and the positive predictive value 25% (95% CI: 17%, 35%). The performance was best in the subgroup of UA patients presenting with oligoarthritis (18% developed RA): the positive predictive value was 36% (95% CI: 23%, 52%), the negative predictive value was 98% (95% CI: 88%, 100%), the sensitivity was 93% (95% CI: 70%, 99%) and the specificity was 63% (95% CI: 51%, 74%).

**Conclusion.** MRI contributes to the identification of UA patients who will develop RA, mostly in UA patients presenting with oligoarthritis.

**Key words:** early rheumatoid arthritis, rheumatoid arthritis, magnetic resonance imaging

## Rheumatology key messages

- MRI-detected tenosynovitis is associated with RA development in unclassified arthritis patients independent of other inflammatory measures.
- MRI tenosynovitis has a high negative predictive value for RA, and the positive predictive value is limited.
- MRI is of most diagnostic use in unclassified arthritis patients presenting with oligoarthritis (2–4 swollen joints).

## Introduction

Patients with RA should receive disease-modifying treatment (DMARDs) as soon as possible because this increases the chance of a better disease outcome [1, 2]. In some RA patients, the classic phenotype has not yet completely developed at the first presentation, hampering prompt diagnosis of RA. To improve early identification, the 2010 ACR/EULAR classification criteria for RA have

<sup>1</sup>Department of Rheumatology, <sup>2</sup>Department of Radiology, <sup>3</sup>Department of Clinical Epidemiology and <sup>4</sup>Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands  
Submitted 28 August 2016; revised version accepted 21 March 2017

Correspondence to: Wouter P. Nieuwenhuis, Department of Rheumatology C1-R, Leiden University Medical Center, PO Box 9600, Leiden 2300RC, The Netherlands.  
E-mail: W.P.Nieuwenhuis@lumc.nl

been developed [3]. These novel criteria do indeed identify RA patients earlier in time than the 1987 ACR classification criteria [4]. However, timely diagnosis is still impossible in some patients: up to 25% of patients presenting with recent-onset arthritis who cannot be classified by the 2010 criteria and have unclassified arthritis (UA) develop RA later on (typically within 1 year) [5]. RA patients who initially present with UA have a disease course equally severe to that of RA patients who already fulfil the criteria at first presentation [6]. Thus, although prompt diagnosis is required, for some RA patients, accurate methods for this are lacking. These patients are mainly ACPA-negative [5]. It has been suggested that novel imaging modalities may be valuable in the early diagnosis of RA [7].

MRI sensitively depicts inflammation; it visualizes synovitis, tenosynovitis and bone marrow oedema (BME). BME (also called osteitis in RA) is not depicted by other imaging modalities [8–10]. Hand and foot MRI is increasingly used as a measure of outcome in clinical trials [11]. Because MRI detects subclinical inflammation (not evident at physical examination) in patients presenting with early arthritis, and MRI-detected inflammation is associated with erosive progression [12], it is thought that MRI may have a role in the diagnostic process of RA. The use of MRI for the early diagnosis of RA is recommended by a taskforce of the EULAR, but it was acknowledged that the evidence supporting this recommendation is low [7]. Previous studies on this subject included relatively low numbers of patients ( $n < 50$ ) [13–21], used low-field-strength MRI scanners [14, 18, 22, 23], or studied selected groups of patients [13–25], which hampered extrapolation of results to rheumatologic practice. Finally, the definition of an abnormal MRI varied between different studies [13–25]; no study considered using the findings for a symptom-free control population for defining a cut-off point to distinguish a normal MRI from an abnormal MRI.

We set out to determine the accuracy of hand and foot MRI in identifying those UA patients who are in an early stage of RA. As preparatory work, we made MRI scans of hands and feet of 193 symptom-free persons from the general population and observed that MRI-detected inflammation was quite prevalent, especially at higher age and at preferred locations [26]. We hypothesized that including these findings in the definition of a positive MRI would reduce false-positive findings. Using a high-field-strength MRI scanner on an unselected early arthritis population visiting a rheumatologic outpatient clinic, this study aimed to (i) explore the discriminative value of MRI by comparing the MRI of patients with classifiable RA at presentation with MRI of symptom-free controls and patients with other arthritides and (ii) determine the value of MRI for the identification of those UA patients who are in an early phase of RA. UA patients were followed for RA development over 1 year. Because the differential diagnosis is slightly different for UA patients presenting with mono-, oligo- or polyarthritis, the diagnostic value of MRI was also explored in these subgroups of UA patients.

## Methods

### Setting and patients

The Leiden Early Arthritis Clinic is a longitudinal inception cohort including patients with clinically confirmed arthritis and symptom duration of  $< 2$  years who presented to the Leiden rheumatologic outpatient clinic. This is the only referral centre in a health care region of  $\sim 400\,000$  inhabitants. The cohort was initiated in 1993 [27]. MRI was added to the study protocol in 2010. At first visit, questionnaires were completed by patients and rheumatologists, joint counts were performed, serum samples obtained and an MRI made. From August 2010 to October 2014, 598 consecutively included patients underwent MRI. Gadolinium chelate contrast was not administered in nine patients; those nine patients were excluded from this study. Two weeks after first presentation, when routine laboratory and radiographic results were known (but not MRI results), patients received their diagnosis; classification of RA was done according to the 2010 criteria [3].

The symptom-free volunteers who served as a reference were recruited via advertisements in local newspapers and websites, and had no history of inflammatory rheumatic diseases, no joint symptoms during the last month and no evidence of arthritis at physical examination. A more detailed description of them is provided in reference [26]. This study was approved by the Leiden University Medical Center medical ethics committee, and all participants signed informed consent forms.

### Outcomes

The study consisted of two parts. First, preliminary investigations were performed to explore the potential discriminative value of MRI. Patients who presented with RA were compared with symptom-free controls and with patients with other arthritides. Then the value of MRI was assessed in the target population of patients presenting with UA (flowchart in Supplementary Fig. S1, available at *Rheumatology* Online). These patients were followed for 1 year. The primary outcome was RA development according to the 1987 criteria [28]. Although the 2010 criteria are fulfilled earlier in time, they have a lower specificity than the 1987 criteria, making them less suitable as long-term outcome measure [4, 29]. Furthermore, ACPA-negative patients can only fulfill the 2010 criteria if  $> 10$  joints become involved; hence, they (and this reflects to the ACPA-negative patients) fulfill the 1987 criteria more easily. The secondary outcome was the initiation of DMARDs during the year of follow-up (see supplementary data, section DMARD therapy, for more detail, available at *Rheumatology* Online). Rheumatologists may initiate DMARDs in UA patients if they anticipate that the patient will progress to RA. Early treatment may prevent progression to fulfilment of classification criteria. Compared with the natural course, this may result in an underestimation of the number of UA patients who progress to RA (the primary outcome). The secondary outcome, therefore,

reflects the expert opinion of the rheumatologist on the presence of RA and may circumvent this underestimation.

### MRI and scoring

At baseline, unilateral contrast-enhanced MRIs were made of the second to fifth MCPs, wrist and first to fifth MTP joints of the most painful side, or the dominant side in the case of equally severe symptoms on both sides. MRI was performed on an Musculoskeletal Extreme 1.5 T extremity magnetic resonance (MR) system; see supplementary data, section detailed MRI protocol, available at *Rheumatology* Online, for a detailed description of the protocol. Erosions, BME, synovitis and tenosynovitis were scored as described in the supplementary data, section MRI scoring and dichotomizing, available at *Rheumatology* Online, [30, 31] by two trained readers (W.P.N. and E.C.N., both having scored >800 MRIs), blinded to any clinical data. Within-reader intraclass correlation coefficients for the total RA MRI scoring system (RAMRIS) inflammation scores, based on 40 MRIs scored twice, were, respectively, 0.98 and 0.93; the between-reader intraclass correlation coefficient, based on all 598 scans, was 0.95. The total inflammation score per patient was calculated by summing all BME, synovitis and tenosynovitis scores. The mean for both readers was used for analyses on continuous scores.

The MRI findings in 193 symptom-free persons, who were scanned according to same protocol [26], were used as a reference for dichotomizing the MRI scores: a bone/joint/tendon was considered abnormal for BME/synovitis/tenosynovitis if, according to both readers, the score for that finding was above the 95th percentile of scores at the same location in symptom-free persons of the same age category (18–40, 40–60 or >60 years) [26]. The locations that showed inflammation in >5% of controls are presented in supplementary Table S1, available at *Rheumatology* Online. Subsequently, at the patient level, an MRI was considered abnormal if one (or more) bone/joint/tendon was considered abnormal. (See the supplementary data, section MRI scoring and dichotomizing, available at *Rheumatology* Online, for an example.) In sub-analyses, a bone/joint/tendon was considered abnormal if the score was higher than all scores (100th percentile) of the symptom-free persons of the same age category at the same location [26].

### Analyses

Logistic regression analysis was used to assess the predictive value of MRI in UA patients. The additional value of MRI-detected inflammation to the swollen joint count (SJC) and CRP was evaluated using multivariable logistic regression analyses. Here, an elevated CRP was defined as  $\geq 10$  mg/l and the SJC was categorized into clinically relevant categories, because of high-leverage outliers. Test characteristics and predictive values were determined. Analyses were repeated after stratification for the number of swollen joints. Decision curve analysis [32] was performed to explore the additive value of MRI, also weighting the harms of over- and underprediction of RA

development, comparing the predicted probabilities of models with and without MRI (supplementary data, section decision curve analysis, available at *Rheumatology* Online). Statistical analyses were performed in IBM SPSS ver. 20 and Stata ver. 14.  $P < 0.05$  were considered significant.

## Results

### Study population

A total of 589 early arthritis patients were studied: 229 had RA at presentation, 201 UA and 159 other arthritides. Baseline characteristics are shown in Table 1. The continuous RAMRIS scores in RA patients and UA patients are shown in Table 2.

### Preliminary investigations

Patients presenting with RA ( $n = 229$ ) were first compared with symptom-free controls ( $n = 193$ ) and with early arthritis patients with other arthritides ( $n = 360$ ). The continuous MRI inflammation scores were higher in RA patients than in symptom-free controls (supplementary Table S2, available at *Rheumatology* Online). High continuous MRI inflammation scores were not only observed in RA, but also in some other arthritides, for example, RS3PE, SLE and MCTD (supplementary Fig. S2, available at *Rheumatology* Online). The discriminative value of an abnormal MRI is shown in Table 3. Compared with synovitis and BME, tenosynovitis had the best discriminative accuracy (Table 3). In sub-analyses, a stricter definition for an abnormal MRI was used; these showed similar results (supplementary Table S3, available at *Rheumatology* Online).

### Accuracy of MRI in identifying those UA patients who developed RA within 1 year

The clinical characteristics of the UA patients are shown in supplementary Table S4, available at *Rheumatology* Online. During the 1-year follow-up, 29 of 201 UA patients (14%) progressed to RA and 75 (37%) were prescribed DMARD therapy. Patients who progressed to RA were older and presented with a higher SJC and higher CRP levels than patients who did not progress (supplementary Table S4, available at *Rheumatology* Online). The total MRI inflammation, synovitis and tenosynovitis scores at baseline were higher in the UA patients who developed RA than in those who did not develop RA (all  $P < 0.001$ , supplementary Fig. S3, available at *Rheumatology* Online); the BME scores were similar ( $P = 0.72$ ). An abnormal MRI for any type of inflammation had an odds ratio (OR) for RA development of 7.2 (95% CI: 1.6, 31.2). The ORs of the individual inflammation types were 6.7 (95% CI: 2.4, 18.3) for tenosynovitis, 2.3 (95% CI: 1.0, 5.2) for synovitis and 0.9 (95% CI: 0.4, 2.1) for BME (Table 4). UA patients frequently had an abnormal MRI for several types of inflammation: 24% had tenosynovitis, synovitis and BME, 21% had two types of inflammation, 24% had only tenosynovitis, synovitis or BME and 62 patients (31%) had a normal MRI (supplementary Fig. S4, available at *Rheumatology* Online). Multivariable logistic regression showed that

**TABLE 1** Baseline characteristics of all early arthritis patients and those presenting with RA and with unclassified arthritis

Characteristic	All early arthritis patients <i>n</i> = 589	Subgroup RA patients <i>n</i> = 229	Subgroup UA patients <i>n</i> = 201
Age, mean (s.d.)	54.8 (15.5)	55.9 (14.4)	54.1 (15.8)
Female, <i>n</i> (%)	363 (61.6)	155 (67.7)	123 (61.2)
Symptom duration, median (IQR), in weeks	12 (5–26)	15 (8–28)	9 (4–24)
Swollen joint count, median (IQR)	3 (2–7)	6 (2–11)	2 (1–4)
CRP, median (IQR), mg/l	6 (3–17)	9 (3–22)	4 (3–10)
RF positive, <i>n</i> (%)	195 (33.1)	151 (65.9)	19 (9.5)
ACPA positive, <i>n</i> (%)	137 (23.3)	124 (54.1)	8 (4)
Diagnosis at presentation, <i>n</i>			
RA	229		
Unclassified arthritis	201		
PsA or spondyloarthritis	39		
Inflammatory OA	35		
Reactive arthritis	25		
Crystal arthropathy	15		
RS3PE	10		
SLE + MCTD	6		
Other diagnoses	29		

RS3PE: remitting seronegative symmetrical synovitis with pitting oedema.

**TABLE 2** Continuous RA MRI scores of patients who presented with RA or unclassified arthritis

MRI score	RA	UA	UA subgroups		
			Monoarthritis	Oligoarthritis	Poly-arthritis
Total RAMRIS score, median [interquartile range (IQR)]	16.50 (9.00–32.00)	11.00 (4.00–19.50)	7.50 (3.00–15.50)	12.00 (5.00–20.00)	14.00 (6.50–24.00)
Inflammation score, median (IQR)	13.50 (6.50–26.00)	7.50 (2.50–15.50)	5.00 (1.50–10.50)	8.00 (3.50–15.00)	12.00 (4.50–21.00)
BME score, median (IQR)	3.75 (1.25–8.50)	2.00 (0.50–5.00)	1.50 (0.50–4.00)	2.50 (0.50–6.00)	1.50 (0.50–4.50)
Synovitis score, median (IQR)	5.00 (2.50–9.00)	3.00 (1.00–6.00)	2.00 (0.50–5.50)	3.50 (1.00–6.50)	4.00 (1.50–9.00)
Tenosynovitis score, median (IQR)	4.00 (1.50–7.50)	1.50 (0.00–5.00)	1.00 (0.00–3.00)	1.50 (0.00–4.50)	2.00 (0.50–8.00)
Erosion score, median (IQR)	3.00 (1.50–6.00)	2.50 (1.00–5.00)	2.00 (1.00–4.50)	3.00 (1.00–5.50)	2.50 (1.50–5.50)

Subgroups of UA patients are based on the number of inflamed joints at presentation: BME: bone marrow oedema; monoarthritis: 1 clinically swollen joint; oligoarthritis: 2–4 clinically swollen joints; polyarthritis: >4 clinically swollen joints; RAMRIS: RA MRI score; UA: unclassified arthritis.

tenosynovitis was associated with RA development, independent of synovitis and BME (OR = 7.5, 95% CI: 2.4, 23.1; Table 4). Also after adjusting for age, SJC and CRP, an abnormal MRI for tenosynovitis was associated with RA development (OR = 4.2, 95% CI: 1.4, 12.9; Table 4). Similar results were observed with the start of DMARD therapy as outcome (Table 4; supplementary Fig. S3, available at *Rheumatology* Online) and when using a

stricter definition for an abnormal MRI (supplementary Table S5, available at *Rheumatology* Online). In addition to MRI inflammation, MRI-detected erosions were evaluated. These were not associated with RA development in univariable or multivariable analyses (supplementary Table S6, available at *Rheumatology* Online).

Within UA patients, an abnormal MRI for tenosynovitis had better test characteristics for RA development than

**TABLE 3** Preliminary investigations: test characteristics for an abnormal MRI to identify patients clinically presenting with RA

MRI abnormal for	Sensitivity, % (95%CI)	Specificity, % (95%CI)	AUC
RA vs symptom-free controls			
Any inflammation	88% (83, 91%)	71% (64, 77%)	0.79
Bone marrow oedema	61% (55, 67%)	78% (72, 83%)	0.70
Synovitis	66% (59, 71%)	93% (88, 96%)	0.79
Tenosynovitis	75% (69, 80%)	95% (91, 97%)	0.85
RA vs early arthritis patients with other arthritides			
Any inflammation	88% (83, 91%)	33% (28, 38%)	0.60
Bone marrow oedema	61% (55, 67%)	57% (52, 62%)	0.59
Synovitis	66% (59, 71%)	58% (52, 63%)	0.62
Tenosynovitis	75% (69, 80%)	56% (50, 61%)	0.65

Test characteristics of an abnormal MRI for discriminating patients who clinically present with RA from symptom-free controls and patients presenting with other arthritides. MRI abnormal for any inflammation indicates the presence of abnormal bone marrow oedema, synovitis or tenosynovitis. AUC: area under the receiver operating characteristic curve.

**TABLE 4** Results of logistic regression analyses for RA development and DMARD initiation in unclassified arthritis patients

Independent variables	Univariable analyses		Multivariable analysis: types of MRI inflammation		Multivariable analysis: abnormal tenosynovitis adjusted for age, SJC and CRP	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Outcome: RA						
Constant/Intercept			0.06 (-)	<0.001	0.01 (-)	<0.001
MRI abnormal for any inflammation	7.2 (1.6–31.2)	0.009				
MRI abnormal for bone marrow oedema	0.9 (0.4–2.1)	0.87	0.5 (0.2–1.2)	0.14		
MRI abnormal for synovitis	2.3 (1.0–5.2)	0.04	1.2 (0.5–3.2)	0.68		
MRI abnormal for tenosynovitis	6.7 (2.4–18.3)	<0.001	7.5 (2.4–23.1)	<0.001	4.2 (1.4–12.9)	0.01
Age, per year	1.03 (1.00–1.06)	0.02			1.01 (0.97–1.04)	0.68
Swollen joints, 1 joint	Reference				Reference	
2–4 joints	8.3 (1.8–37.5)	0.006			7.5 (1.6–34.8)	0.01
>4 joints	15.5 (3.3–73.6)	0.001			10.4 (2.1–51.5)	0.004
Elevated CRP	3.8 (1.7–8.5)	0.001			2.2 (0.9–5.4)	0.10
Outcome: DMARD initiation						
Constant/Intercept			0.30 (-)	<0.001	0.09 (-)	<0.001
MRI abnormal for any inflammation	2.3 (1.2–4.6)	0.01				
MRI abnormal for bone marrow oedema	1.1 (0.6–2)	0.70	0.7 (0.3–1.3)	0.27		
MRI abnormal for synovitis	2.1 (1.2–3.7)	0.01	1.2 (0.6–2.4)	0.67		
MRI abnormal for tenosynovitis	4.2 (2.3–7.8)	<0.001	4.4 (2.2–9.0)	<0.001	3.0 (1.5–6.0)	0.003
Age, per year	1.03 (1.01–1.05)	0.006			1.01 (0.98–1.03)	0.55
Swollen joints, 1 joint	Reference				Reference	
2–4 joints	2.5 (1.2–5.1)	0.01			2.3 (1.1–4.9)	0.03
>4 joints	6.6 (2.9–15.3)	<0.001			5.2 (2.1–12.7)	<0.001
Elevated CRP	3.0 (1.6–5.7)	0.01			2 (1.0–4.2)	0.06

MRI abnormal for any inflammation indicates the presence of abnormal bone marrow oedema, synovitis or tenosynovitis; OR: odds ratio; SJC: swollen joint count.

BME and synovitis [area under the receiver operating characteristic curve (AUC) of 0.70, vs 0.49 and 0.60]. The positive predictive value of tenosynovitis for RA development was 25% and the negative predictive value 95%

(supplementary Table S7, available at *Rheumatology* Online). Since the association of an abnormal MRI for tenosynovitis with RA development was stronger than that of an abnormal MRI for synovitis or BME, further



analyses were confined to tenosynovitis. Similar results for tenosynovitis were seen using DMARD initiation as the outcome (supplementary Table S7, available at *Rheumatology* Online).

### Accuracy of MRI in subgroups of UA patients presenting with mono-, oligo and polyarthritis

The differential diagnoses for UA patients presenting with monoarthritis (1 swollen joint), oligoarthritis (2–4 joints) and polyarthritis (>4 joints) can differ. Because the value of MRI might also differ in these patients, the value of MRI was explored in these three subgroups. RA development was rare in UA patients presenting with monoarthritis (3%); of the UA patients presenting with oligo and polyarthritis, 18% and 29%, respectively, developed RA (Table 5). The continuous RAMRIS scores of the three subgroups are shown in Table 2. In UA patients with mono- and polyarthritis, an abnormal MRI for tenosynovitis was not associated with RA development (Table 5). In UA patients with oligoarthritis, in contrast, an abnormal MRI for tenosynovitis was associated with RA development ( $P < 0.001$ ), the sensitivity was 93%, specificity 63%, positive predictive value 36% and negative predictive value 98%. Similar results were found when using initiation of DMARD therapy as the outcome (supplementary Table S8, available at *Rheumatology* Online). When a stricter definition of an abnormal MRI was used, the results were similar (supplementary Table S9, available at *Rheumatology* Online).

### Decision curve analyses

In all UA patients and in the subgroup of UA patients presenting with oligoarthritis, models with and without abnormal MRI tenosynovitis were compared (supplementary Table S10, available at *Rheumatology* Online). This showed a higher net benefit for the model with MRI in both analyses (Fig. 1).

## Discussion

It is recommended by the EULAR that treatment of RA should be initiated as soon as possible [33]. Early treatment requires early identification of RA. This is difficult if patients present with UA. It is inextricably linked to early recognition that the phenotype may not yet be completely matured; additional tests are therefore needed. When using the 2010 criteria, UA patients are mainly ACPA-negative, as was also shown here [5, 34]. The regular predictors such as CRP and the number of swollen joints also have a limited predictive value. As it has been advocated that MRI-detected inflammation is valuable for the early identification of RA [7], this study determined the diagnostic accuracy of hand and foot MRI in 2010 UA patients. Although an abnormal MRI did not yield high absolute risks for RA, the data showed that MRI contributed to the identification of UA patients that will progress to RA. Of all types of inflammation, tenosynovitis had the best accuracy and, of all UA patients, the test characteristics were highest in the subgroup of UA patients who

presented with oligoarthritis. Furthermore, the absence of MRI-detected inflammation made progression to RA highly unlikely.

Generally, the development of a diagnostic tool starts with comparing established patients with controls. This allows testing of the chosen cut-off value. The disadvantage is that this generally results in accuracies that are misleadingly high [35, 36]. Subsequently, the test needs to be evaluated in clinically relevant settings. We set out to use this approach. We used information on MRIs of symptom-free persons from the general population to define an abnormal test and compared the MRI findings for patients who presented with RA with those of symptom-free controls and with patients with other arthritides. Indeed, we observed that the test characteristics were lower when comparing RA with other arthritides than with healthy controls; this is also in line with a smaller previous study that showed that early arthritis patients with other arthritides also show inflammation of the hands and feet on MRI [37]. After these explorative studies, the value of MRI was assessed in the clinically relevant setting of UA.

At baseline, RA was defined according to the 2010 criteria, and UA patients did not fulfil these criteria. Ninety-six percent of 2010 UA patients were ACPA-negative and only 4% was ACPA-positive. This is in line with the composition of the 2010 criteria, where ACPA-positive patients can fulfil the criteria with one (or more) swollen joint and ACPA-negative patients require >10 swollen joints [3]. This suggests that the 2010 criteria are less sensitive for the early detection of ACPA-negative RA. Indeed, a recent study proved that ACPA-negative RA patients had more extensive inflammation than ACPA-positive RA patients [38]. Consequently, ACPA-negative patients are nowadays more frequently classified as UA; this was also shown in our data.

Fulfilling the 1987 criteria was the primary outcome because these criteria had a higher specificity than the 2010 criteria [4, 29] and because ACPA-negative UA patients can only become 2010-positive when they develop >10 involved joints; also, DMARDs may be initiated before the disease is as advanced. Intuitively it feels contradictory not to use the 2010 criteria as the outcome, but we balanced up the characteristics of the different criteria (the 2010 criteria being sensitive and fulfilled earlier than the 1987 criteria, the 1987 criteria being more specific over time). In our data only 5% of ACPA-negative patients fulfilled the 2010 criteria after 1-year, whereas 14% fulfilled the 1987 criteria and 36% were treated with DMARDs. Hence, our data confirm the observation that ACPA-negative patients fulfil the 1987 criteria more easily than the 2010 criteria. Still, in both ACPA-negative and ACPA-positive patients, treatment may have resulted in a decreased percentage of patients developing RA. Therefore DMARD initiation was also studied as outcome.


The present data emphasize that MRI is valuable in (APCA-negative) UA, especially in ACPA-negative UA patients presenting with oligoarthritis. Only 3% of ACPA-negative patients presenting with monoarthritis progressed to RA; with this low prior risk a predictive effect

**TABLE 5** Test characteristics of an abnormal MRI for tenosynovitis for RA development in unclassified arthritis patients

All UA patients, <i>n</i> (%)	RA 29 (14)	No RA 172 (86)	<i>P</i> -value	Sens., % (95% CI)	Spec., % (95% CI)	PPV, % (95% CI)	NPV, % (95% CI)	LR+, % (95% CI)	LR-, % (95% CI)	AUC
MRI-TS+	24	72	<0.001	83 (65, 92)	58 (51, 65)	25 (17, 35)	95 (89, 98)	1.98 (1.55, 2.52)	0.30 (0.13, 0.66)	0.70
MRI-TS-	5	100								
CRP+	15	38	0.001	52% (34, 69)	78 (71, 83)	28 (18, 42)	91 (85, 94)	2.34 (1.49, 3.67)	0.62 (0.42, 0.91)	0.65
CRP-	14	134								
MRI-TS+	15	22	0.002	100 (80, 100)	42 (28, 58)	41 (26, 57)	100 (81, 100)	1.73 (1.32, 2.27)	-	0.71
MRI-TS-	0	16								
CRP+	9	50	0.05	64 (3, 84)	63 (54, 70)	15 (8, 27)	94 (88, 98)	1.72 (1.10, 2.70)	0.57 (0.28, 1.16)	0.63
CRP-	5	84								
Subgroup: monoarthritis, <i>n</i> (%)	2 (3)	75 (97)								
MRI-TS+	1	29	0.99	50 (9, 91)	61 (50, 72)	3 (1, 17)	98 (89, 100)	1.29 (0.31, 5.32)	0.82 (0.20, 3.30)	0.56
MRI-TS-	1	46								
Subgroup: oligoarthritis, <i>n</i> (%)	15 (18)	68 (82)								
MRI-TS+	14	25	<0.001	93 (70, 99)	63 (51, 74)	36 (23, 52)	98 (88, 100)	2.54 (1.81, 3.57)	0.11 (0.02, 0.71)	0.78
MRI-TS-	1	43								
CRP+	8	14	0.020	53 (30, 75)	79 (68, 87)	36 (20, 57)	89 (78, 94)	2.59 (1.33, 5.04)	0.59 (0.34, 1.02)	0.66
CRP-	7	54								
CRP+	8	8	0.051	100 (68, 100)	43 (21, 67)	50 (28, 72)	100 (61, 100)	1.75 (1.11, 2.75)	-	0.71
MRI-TS+	0	6								
MRI-TS-	6	17	0.009	86 (49, 97)	69 (55, 79)	26 (13, 46)	97 (87, 100)	2.72 (1.66, 4.47)	0.21 (0.03, 1.29)	0.77
CRP-	1	37								
Subgroup: polyarthritis, <i>n</i> (%)	12 (29)	29 (71)								
MRI-TS+	9	18	0.49	75 (47, 91)	38 (23, 56)	33 (19, 52)	79 (52, 92)	1.21 (0.78, 1.86)	0.66 (0.22, 1.95)	0.56
MRI-TS-	3	11								

Mono-, oligo- and polyarthritis, respectively: swollen joint count of 1, 2–4 and >4; RA, fulfilment of the 1987 RA criteria within the first year; *P*, *P*-values of Chi-square test (or Fisher's exact test when appropriate); Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR-: negative likelihood ratio; AUC: area under the receiver operating characteristic curve; MRI-TS: abnormal MRI-detected tenosynovitis; MRI-TS+: presence of abnormal MRI-detected tenosynovitis; MRI-TS-: absence of abnormal MRI-detected tenosynovitis; CRP+: elevated CRP; CRP-: normal CRP.

**Fig. 1** Decision curve analysis comparing models with and without MRI-detected tenosynovitis for identification of RA progression in unclassified arthritis patients



Decision curve analysis demonstrating the net benefit of different diagnostic models (supplementary Table S10, available at *Rheumatology* Online) for identifying the patients who progress to RA among all unclassified arthritis (UA) patients (**A**) and among the subgroup of UA patients who presented with oligoarthritis (**B**). The net benefit (*y*-axis) is measured as the rate of correctly diagnosed patients developing RA within the first year without additional false-positive identified patients. The threshold probability (*x*-axis) represents the probability at which the benefit of early diagnosis is considered equivalent to the harm of overdiagnosis.

of MRI could not be detected. Also, in ACPA-negative patients presenting with polyarthritis, a predictive effect of MRI was not found; presumably in patients who presented with polyarthritis already, information on MRI-detected local joint inflammation was not of additional value.

The present finding that tenosynovitis was most discriminative is in line with previous studies [14, 20, 22, 23]. Interestingly, tenosynovitis was also an early phenomenon in mice models of induced arthritis [39] and has recently also been shown to be predictive for the development of clinically apparent arthritis in patients who present with clinically suspect arthralgia [40]. Tenosynovitis is also detectable with US. Although some studies suggested that US is less sensitive than MRI in detecting tenosynovitis, the question of whether MRI can be replaced with US in UA patients when identifying patients with impending RA remains to be answered [20, 41, 42].

Importantly, the early arthritis patients studied were consecutively seen at the outpatient clinic and included in the cohort without further selection other than recent-onset arthritis [27]; this allows extrapolation of findings. Other strong elements are the comprehensive approach and the sample size. This study contains by far the largest number of consecutive included early arthritis patients with MRI data thus far. High-quality MRI data were obtained; we used a superconductive 1.5 T system with powerful gradients, allowing small acquisition matrices

with relatively high SNR and frequency-selective fat suppression.

BME was assessed on contrast-enhanced T1-weighted fat-saturated sequences; RAMRIS suggests STIR/T2-sequences (see supplementary data, section detailed MRI protocol, available at *Rheumatology* Online) [30]. Previous studies, in diverse patient populations, have shown high similarities for BME between these sequences [43–45], and both sequences are recommended by the European Society of Skeletal Radiology (ESSR) [46].

Previously, both in our study and the research of others, BME has been shown to be predictive for erosive progression in RA patients [47–50]. In the present study, BME and erosions were not predictive for RA development in UA patients. Possibly, this is related to the fact that most UA patients were ACPA-negative, or to the fact that predictors for erosive progression are different from those predicting RA development. Apparently, different markers perform differently when used in slightly different types of patients, in different disease phases, and with respect to different outcomes.

Our study has several limitations. First, the sample set: although we studied a large group of 201 UA patients, only 29 of these patients developed RA. This also resulted in a low number of cases in the subgroups of mono-, oligo- and polyarthritis. In general, low numbers of cases lead to a higher probability of a type II error. The RAMRIS method was used to score the MRIs. This method is the



only validated method for evaluating hand and foot MRIs and is suitable for research, but it was not designed for diagnostic purposes. RAMRIS scoring is time-consuming, rheumatologists and radiologists are generally not experienced with the method, and the reproducibility may be moderate if readers are insufficiently trained. This may hamper direct clinical implementation. After showing the continuous MRI scores, the most important analyses were done by comparing abnormal with normal MRI results. Dichotomization generally leads to loss of information and possibly loss of discriminative value. However, using continuous scores would have hampered the use of findings done in symptom-free controls. More work is needed in order to make MRI feasible for diagnostic use. As in other fields of radiology, a small set of well-defined imaging parameters are needed to allow the use of MRI in the differential diagnostic process in a subjective clinical environment.

We did not address the cost-effectiveness of MRI. Although MRI is relatively expensive, the possible benefits of an early RA diagnosis could be a multitude when resulting in reduced disability and reduced use of biologics. We also did not evaluate to what extent it is required to scan hand and foot joints, or if a limited region would be equally informative. These are subjects for further research.

In conclusion, this study revealed that MRI-detected inflammation contributes to the identification of UA patients who will develop RA. MRI-detected tenosynovitis was most helpful, and the accuracy was the highest in UA patients who presented with oligoarthritis. Furthermore, RA was unlikely to develop in UA patients with a normal MRI. This comprehensive study therefore indicates that MRI is of help in the diagnostic process of RA.

## Acknowledgements

**Author contributions:** Author access to data: W.P.N. and A.H.Mv.Hv.M. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: W.P.N., J.L.B., T.W.J.H., Sl.C., M.R. and A.H.Mv.Hv.M. Acquisition, analysis or interpretation of data: W.P.N., H.Wv.S., L.M., E.C.N., J.L.B., T.W.J.H., Sl.C., M.R. and A.H.Mv.Hv.M. Drafting of the manuscript: W.P.N. and A.H.Mv.Hv.M. Critical revision of the manuscript for important intellectual content: W.P.N., H.Wv.S., L.M., E.C.N., J.L.B., T.W.J.H., Sl.C., M.R. and A.H.Mv.Hv.M. Statistical analysis: W.P.N. and Sl.C. Obtaining funding: A.H.Mv.Hv.M. Administrative, technical or material support: W.P.N., H.Wv.S., L.M., E.C.N., J.L.B., T.W.J.H., Sl.C., M.R. and A.H.Mv.Hv.M. Supervision: J.L.B., T.W.J.H., M.R. and A.H.Mv.Hv.M.

**Funding:** This work was supported by the Dutch Arthritis Foundation and the Netherlands Organization for Health Research and Development (Vidi grant). The funding sources had no role in the design and conduct of the study; collection, management, analysis and

interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.

**Disclosure statement:** The authors have declared no conflicts of interest.

## Supplementary data

Supplementary data are available at *Rheumatology Online*.

## References

- 1 van der Linden MPM, le Cessie S, Raza K *et al*. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum* 2010;62:3537–46.
- 2 Combe B, Landewe R, Lukas C *et al*. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2007;66:34–45.
- 3 Aletaha D, Neogi T, Silman AJ *et al*. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:2569–81.
- 4 Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis* 2014;73:114–23.
- 5 Krabben A, Abhishek A, Britsemmer K *et al*. Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis. *Rheumatology* 2013;52:1265–70.
- 6 Aken JV, Dongen HV, Cessie SI *et al*. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. *Ann Rheum Dis* 2006;65:20–5.
- 7 Colebatch AN, Edwards CJ, Østergaard M *et al*. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. *Ann Rheum Dis* 2013;72:804–14.
- 8 Jimenez-Boj E, Nöbauer-Huhmann I, Hanslik-Schnabel B *et al*. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. *Arthritis Rheum* 2007;56:1118–24.
- 9 Dalbeth N, Smith T, Gray S *et al*. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. *Ann Rheum Dis* 2009;68:279–82.
- 10 McQueen FM, Gao A, Østergaard M *et al*. High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. *Ann Rheum Dis* 2007;66:1581–7.
- 11 Peterfy C, Østergaard M, Conaghan PG. MRI comes of age in RA clinical trials. *Ann Rheum Dis* 2013;72:794–6.
- 12 Krabben A, Stomp W, Huizinga TWJ *et al*. Concordance between inflammation at physical examination and on MRI

- in patients with early arthritis. *Ann Rheum Dis* 2013;74:506–12.
- 13 Sugimoto H, Takeda A, Masuyama J, Furuse M. Early-stage rheumatoid arthritis: diagnostic accuracy of MR imaging. *Radiology* 1996;198:185–92.
  - 14 Klarlund M, Østergaard M, Jensen KE *et al.* Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. *Ann Rheum Dis* 2000;59:521–8.
  - 15 Sugimoto H, Takeda A, Hyodoh K. Early-stage rheumatoid arthritis: prospective study of the effectiveness of MR imaging for diagnosis. *Radiology* 2000;216:569–75.
  - 16 Boutry N, Hachulla É, Flipo R-M, Cortet B, Cotten A. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren Syndrome. *Radiology* 2005;236:593–600.
  - 17 Solau-Gervais E, Legrand J-L, Cortet B, Duquesnoy B, Flipo R-M. Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study. *J Rheumatol* 2006;33:1760–5.
  - 18 Duer A, Østergaard M, Hørslev-Petersen K, Valø J. Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis. *Ann Rheum Dis* 2008;67:48–51.
  - 19 Mori G, Tokunaga D, Takahashi KA *et al.* Maximum intensity projection as a tool to diagnose early rheumatoid arthritis. *Mod Rheumatol* 2008;18:247–51.
  - 20 Navalho M, Resende C, Rodrigues AM *et al.* Bilateral evaluation of the hand and wrist in untreated early inflammatory arthritis: a comparative study of ultrasonography and magnetic resonance imaging. *J Rheumatol* 2013;40:1282–92.
  - 21 Ji L, Li G, Xu Y, Zhou W, Zhang Z. Early prediction of rheumatoid arthritis by magnetic resonance imaging in the absence of anti-cyclic citrullinated peptide antibodies and radiographic erosions in undifferentiated inflammatory arthritis patients: a prospective study. *Int J Rheum Dis* 2015;18:859–65.
  - 22 Eshed I, Feist E, Althoff CE *et al.* Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis. *Rheumatology* 2009;48:887–91.
  - 23 Duer-Jensen A, Hørslev-Petersen K, Hetland ML *et al.* Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. *Arthritis Rheum* 2011;63:2192–202.
  - 24 Tamai M, Kawakami A, Uetani M *et al.* The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis. *Ann Rheum Dis* 2006;65:133–4.
  - 25 Tamai M, Kawakami A, Uetani M *et al.* A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. *Arthritis Care Res* 2009;61:772–8.
  - 26 Mangnus L, van Steenberg HW, Reijnen M, van der Helm-van Mil AHM. Magnetic resonance imaging-detected features of inflammation and erosions occur in symptom-free persons from the general population. *Arthritis Rheumatol* 2016;68:2593–602.
  - 27 de Rooy DPC, van der Linden MPM, Knevel R, Huizinga TWJ, van der Helm-van Mil AHM. Predicting arthritis outcomes—what can be learned from the Leiden Early Arthritis Clinic? *Rheumatology* 2011;50:93–100.
  - 28 Arnett FC, Edworthy SM, Bloch DA *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315–24.
  - 29 van der Linden MPM, Knevel R, Huizinga TWJ, van der Helm-van Mil AHM. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. *Arthritis Rheum* 2011;63:37–42.
  - 30 Østergaard M, Peterfy C, Conaghan P *et al.* OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. *J Rheumatol* 2003;30:1385–6.
  - 31 Haavardsholm EA, Østergaard M, Ejbjerg BJ, Kvan NP, Kvien TK. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. *Ann Rheum Dis* 2007;66:1216–20.
  - 32 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006;26:565–74.
  - 33 Smolen JS, Landewé R, Breedveld FC *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 2014;73:492–509.
  - 34 Krabben A, Huizinga TWJ, Mil AHM, van der H. Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis. *Ann Rheum Dis* 2012;71:238–41.
  - 35 Schünemann HJ, Oxman AD, Brozek J *et al.* GRADE: assessing the quality of evidence for diagnostic recommendations. *Evid Based Med* 2008;13:162–3.
  - 36 Rutjes AWS, Reitsma JB, Nisio MD *et al.* Evidence of bias and variation in diagnostic accuracy studies. *Can Med Assoc J* 2006;174:469–76.
  - 37 Stomp W, Krabben A, van der Heijde D *et al.* Are rheumatoid arthritis patients discernible from other early arthritis patients using 1.5T extremity magnetic resonance imaging? A large cross-sectional study. *J Rheumatol* 2014;41:1630–7.
  - 38 Nordberg LB, Lillegraven S, Lie E *et al.* Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. *Ann Rheum Dis* 2017;76:341–5.
  - 39 Hayer S, Redlich K, Korb A *et al.* Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. *Arthritis Rheum* 2007;56:79–88.

- 40 van Steenberg HW, Mangnus L, Reijnders M, Huizinga TWJ, van der Helm-van Mil AHM. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. *Ann Rheum Dis* 2016;75:1824–30.
- 41 Wakefield RJ, O'Connor PJ, Conaghan PG *et al.* Finger tendon disease in untreated early rheumatoid arthritis: a comparison of ultrasound and magnetic resonance imaging. *Arthritis Care Res* 2007;57:1158–64.
- 42 Backhaus M, Kamradt T, Sandrock D *et al.* Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. *Arthritis Rheum* 1999;42:1232–45.
- 43 Stomp W, Krabben A, van der Heijde D *et al.* Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema? *Eur Radiol* 2014;24:2614–22.
- 44 Schmid MR, Hodler J, Vienne P, Binkert CA, Zanetti M. Bone marrow abnormalities of foot and ankle: STIR versus T1-weighted contrast-enhanced fat-suppressed spin-echo MR imaging. *Radiology* 2002;224:463–9.
- 45 Mayerhoefer ME, Breitschneider MJ, Kramer J *et al.* STIR vs. T1-weighted fat-suppressed gadolinium-enhanced MRI of bone marrow edema of the knee: computer-assisted quantitative comparison and influence of injected contrast media volume and acquisition parameters. *J Magn Reson Imaging* 2005;22:788–93.
- 46 Sudot-Szopińska I, Jurik A, Eshed I *et al.* Recommendations of the ESSR arthritis subcommittee for the use of magnetic resonance imaging in musculoskeletal rheumatic diseases. *Semin Musculoskelet Radiol* 2015;19:396–411.
- 47 Nieuwenhuis WP, van Steenberg HW, Stomp W *et al.* The course of bone marrow edema in early undifferentiated arthritis and rheumatoid arthritis; a longitudinal magnetic resonance imaging study at bone level. *Arthritis Rheumatol* 2016;68:1080–8.
- 48 Hetland ML, Stengaard-Pedersen K, Junker P *et al.* Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. *Ann Rheum Dis* 2010;69:1789–95.
- 49 Haavardsholm EA, Bøyesen P, Østergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. *Ann Rheum Dis* 2008;67:794–800.
- 50 McQueen FM, Stewart N, Crabbe J *et al.* Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. *Ann Rheum Dis* 1999;58:156–63.